Johnson & Johnson (JNJ)
Johnson & Johnson Reaches Deal With Trump Administration to Lower Drug Prices
The agreement provides Johnson & Johnson's pharmaceutical products an exemption from tariffs, the company said.
Johnson & Johnson reaches deal with US government to lower drug prices
Johnson & Johnson said on Thursday it has reached a agreement with U.S. President Donald Trump's administration to cut drug prices for Americans in exchange for exemptions from U.S. tariffs.
J&J's Innovative Medicine Segment in Q4: Here's What to Watch
JNJ's Innovative Medicine segment shows resilience ahead of Q4 results, with key drugs driving growth despite Stelara biosimilars and Part D headwinds.
JNJ's Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance the drug into phase III.
JNJ vs. AZN: Which Drug Stock Comes Out on Top for Investors?
J&J's diversified pharma and MedTech strength stacks up against AstraZeneca's oncology-led growth as investors weigh stability versus faster expansion.
Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $204.31, denoting a -1.47% move from the preceding trading day.
Wall Street Analysts Think Johnson & Johnson (JNJ) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Jim Cramer Says ‘The Year of Magical Investing' Is Over—Here's What To Do Now
CNBC's "Mad Money" host is waving the yellow flag.
More Upside For JNJ Stock In 2026?
Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was spun off as Kenvue.
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling
The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
